Many of our patients have intolerable GI side effects from metformin. We use ER to try to decrease these, but that doesn’t always work. If they have these symptoms, I recommend they take it slow and take it after they eat. If they still have problems, I recommend they break the tablet to 250mg, even though the label may say one shouldn’t break the tablet.
Read More »Production Assistant, Diabetes In Control
Dr. Jeffrey Mechanick Part 1, Nutrition and Lifestyle
In part 1 of this Exclusive Interview meet Dr. Mechanick, current president of American College of Endocrinology, who has a focus on nutrition and lifestyle.
Read More »International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #48: Biosynthesis, secretion, and action of glucagon Part 2 of 4
Physiologic effects of glucagon: Glucagon acts through binding to specific receptors located at the target cell plasma membrane. The major common effect of glucagon is to activate adenylate cyclase and to increase the intracellular production of cAMP. There is considerable evidence that binding of glucagon to its receptor activates an intermediate transduction process that involves the participation of guanosine triphosphate (GTP), divalent cations, and adenosine (or other similar natural substances).
Read More »Dr. Claude Lardinois Part 4 – Interpreting Genetics Testing
Dr. Claude Lardinois talks with Diabetes in Control Associate Medical Editor Joy Pape at the 2016 AACE Meeting. In part 4, the final installment of this Exclusive Interview, Dr. Lardinois talks about implementing genetic testing and explains his interpretation of the testing to patients. Dr. Claude Lardinois, M.D., FACP, FACE, …
Read More »Dr. Claude Lardinois Part 3 – Heart Disease and The Genetics Connection
Dr. Claude Lardinois talks with Diabetes in Control Associate Medical Editor Joy Pape at the 2016 AACE Meeting. In part 3 of this Exclusive Interview, Dr. Lardinois explains his focus on heart disease over A1C and the connection of genetics in determining risk. Dr. Claude Lardinois, M.D., FACP, FACE, MACN, …
Read More »Dr. Claude Lardinois Part 2 – SGLT-2 and Amputations
Dr. Claude Lardinois talks with Diabetes in Control Associate Medical Editor Joy Pape at the 2016 AACE Meeting. In part 2 of this Exclusive Interview, Dr. Lardinois explains his emphasis on the importance of quitting smoking to decrease the risk of amputations. Dr. Claude Lardinois, M.D., FACP, FACE, MACN, has …
Read More »Dr. Claude Lardinois, Part 1 – An Award-Winning Fellow
Dr. Claude Lardinois talks with Diabetes in Control Associate Medical Editor Joy Pape at the 2016 AACE Meeting. In part 1 of this Exclusive Interview, Dr. Lardinois accepts his win as a Fellow of the American College of Endocrinology. Dr. Claude Lardinois, M.D., FACP, FACE, MACN, has been an endocrinologist …
Read More »Claude Lardinois Full Interview
Dr. Claude Lardinois talks with Diabetes in Control Associate Medical Editor Joy Pape at the 2016 AACE Meeting. Dr. Lardinois discusses amputations and SGLT-2s, and genetic risk factors for cardiovascular issues in diabetes patients. Dr. Claude Lardinois, M.D., FACP, FACE, MACN, has been an endocrinologist in Reno, Nevada for more …
Read More »Diabetes Research Platform
Which party do you believe will be a champion for diabetes research, prevention, and treatment? 1) Democrats 2) Republicans 3) Independents 4) None of the above 5) Not sure Follow the link to share your opinion and see what your colleagues think.
Read More »Take Control of Type 2 Diabetes with the FREE Low Carb Program App
A 10-week low-carb education program developed with the help of 20,000 people with T2 and based on the latest research. Benefits of a low-carb diet include lower blood glucose levels, less dependence on medication, and improved cholesterol levels. Based on the latest research, the Low Carb Program app tells you all you need to know in 10 weeks.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.